0.7542
price down icon3.86%   -0.0303
after-market After Hours: .75 -0.0042 -0.56%
loading

Atossa Therapeutics Inc Stock (ATOS) Latest News

pulisher
Feb 24, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price - Investing.com

Feb 24, 2025
pulisher
Feb 20, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

Atossa Therapeutics reports progress in breast cancer treatments - MSN

Feb 20, 2025
pulisher
Feb 19, 2025

Atossa Therapeutics Inc (ATOS) looking to reclaim success with recent performance - SETE News

Feb 19, 2025
pulisher
Feb 14, 2025

Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Bought by SG Americas Securities LLC - Defense World

Feb 13, 2025
pulisher
Feb 10, 2025

Market Watch Highlights: Atossa Therapeutics Inc (ATOS) Ends on an Downturn Note at 0.77 - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Investing in Atossa Therapeutics Inc (ATOS) Is Getting More Attractive - Knox Daily

Feb 10, 2025
pulisher
Feb 08, 2025

Atossa Therapeutics faces patent setback, continues development - MSN

Feb 08, 2025
pulisher
Feb 07, 2025

FY2029 Earnings Forecast for ATOS Issued By HC Wainwright - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

What is HC Wainwright's Estimate for ATOS FY2029 Earnings? - MarketBeat

Feb 06, 2025
pulisher
Feb 05, 2025

Atossa Therapeutics Congratulates Board Director Dr. Tessa - GlobeNewswire

Feb 05, 2025
pulisher
Feb 05, 2025

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times

Feb 05, 2025
pulisher
Feb 05, 2025

Major CDC Grant Fuels Revolutionary Breast Cancer Care Program in NYC - StockTitan

Feb 05, 2025
pulisher
Feb 04, 2025

Do investors need to be concerned about Atossa Therapeutics Inc (ATOS)? - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Financial Metrics Unveiled: Atossa Therapeutics Inc (ATOS)’s Key Ratios in the Spotlight - The Dwinnex

Feb 04, 2025
pulisher
Feb 03, 2025

Equities Analysts Set Expectations for ATOS FY2029 Earnings - Defense World

Feb 03, 2025
pulisher
Feb 02, 2025

Atossa Therapeutics (NASDAQ:ATOS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Feb 02, 2025
pulisher
Feb 01, 2025

JPMorgan Chase & Co. Acquires 95,643 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Feb 01, 2025
pulisher
Feb 01, 2025

HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World

Feb 01, 2025
pulisher
Jan 31, 2025

Atossa Genetics stock hits 52-week low at $0.75 - MSN

Jan 31, 2025
pulisher
Jan 31, 2025

Atossa Genetics stock hits 52-week low at $0.75 By Investing.com - Investing.com Australia

Jan 31, 2025
pulisher
Jan 30, 2025

Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen - Marketscreener.com

Jan 30, 2025
pulisher
Jan 30, 2025

Troy Minerals Inc. (TROY-CN) QuotePress Release - The Globe and Mail

Jan 30, 2025
pulisher
Jan 30, 2025

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Atossa's Patent Strategy Shift: New Endoxifen Patent Reinforces 118+ Protected Claims - StockTitan

Jan 30, 2025
pulisher
Jan 27, 2025

Option Volatility And Earnings Report For January 2731 - The Globe and Mail

Jan 27, 2025
pulisher
Jan 27, 2025

Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail

Jan 27, 2025
pulisher
Jan 23, 2025

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 - The Manila Times

Jan 23, 2025
pulisher
Jan 23, 2025

Atossa Therapeutics reports progress in breast cancer treatments By Investing.com - Investing.com South Africa

Jan 23, 2025
pulisher
Jan 23, 2025

Atossa's Endoxifen Shows Breakthrough 23.5% Breast Density Reduction in Phase 2 Cancer Trial - StockTitan

Jan 23, 2025
pulisher
Jan 21, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stake Raised by Barclays PLC - Defense World

Jan 21, 2025
pulisher
Jan 13, 2025

Jane Street Group LLC Trims Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Jan 13, 2025
pulisher
Jan 08, 2025

Atossa Therapeutics (NASDAQ: ATOS) vs. NLS Pharmaceutics (NASDAQ: NLSP): A Comparative Analysis - HPBL

Jan 08, 2025
pulisher
Jan 08, 2025

Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World

Jan 08, 2025
pulisher
Jan 07, 2025

The Hidden Connection: Dr. Steven Quay on Alcohol and Cancer Risk - Cville Right Now

Jan 07, 2025
pulisher
Jan 06, 2025

Atossa Therapeutics Applauds U.S. Surgeon General’s - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

Surgeon General Links Alcohol to 44,000 Annual Breast Cancer Cases, Atossa Backs Warning - StockTitan

Jan 06, 2025
pulisher
Jan 06, 2025

Geode Capital Management LLC Has $4.28 Million Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Jan 06, 2025
pulisher
Jan 06, 2025

Barclays PLC Has $255,000 Stock Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Jan 06, 2025
pulisher
Jan 01, 2025

State Street Corp Has $2.63 Million Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Jan 01, 2025
$74.40
price up icon 0.53%
$22.96
price up icon 2.04%
$33.69
price down icon 0.33%
$357.50
price down icon 0.20%
$110.97
price down icon 5.14%
biotechnology ONC
$259.70
price up icon 0.47%
Cap:     |  Volume (24h):